Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. - Wikidata - wikimedia - TriplyDB

Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.

Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.

http://www.wikidata.org/entity/Q33527690

about

Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy Cardio-oncology: Concepts and practice Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol Myocardial strain imaging: how useful is it in clinical decision making?Cardiac toxicity in cancer survivors Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors Evaluation and management of patients with heart disease and cancer: cardio-oncology The prevention, detection and management of cancer treatment-induced cardiotoxicity: a meta-review Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma Cardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and Management Cardiac risk in the treatment of breast cancer: assessment and management.Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs Myocardial creatine levels do not influence response to acute oxidative stress in isolated perfused heart Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.Cancer treatment-related cardiac toxicity: prevention, assessment and management.Strain imaging to detect cancer therapeutics-related cardiac dysfunction: are we there yet?Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.Subclinical ventricular dysfunction detected by speckle tracking two years after use of anthracycline.Cardiac complications of chemotherapy: role of imaging.Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies.Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs.Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage.Assessing the Cardiac Toxicity of Chemotherapeutic Agents: Role of Echocardiography.Heart failure following cancer treatment: characteristics, survival and mortality of a linked health data analysis.Diagnostic Strategies for Early Recognition of Cancer Therapeutics-Related Cardiac Dysfunction.Late effects of blood and marrow transplantation.Anthracycline induced cardiotoxicity: biomarkers and "Omics" technology in the era of patient specific care.Cardio-oncology: what you need to know now for clinical practice and echocardiography.Early Detection and Serial Monitoring of Anthracycline-Induced Cardiotoxicity Using T1-mapping Cardiac Magnetic Resonance Imaging: An Animal Study.Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives.Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure.Assessment of cardiotoxicity with cardiac biomarkers in cancer patients.Hospital-level variation in use of cardiovascular testing for adults with incident heart failure: findings from the cardiovascular research network heart failure study.Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab.Safety and efficacy of aerobic training in patients with cancer who have heart failure: an analysis of the HF-ACTION randomized trial 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by repres Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?Chemotherapy-induced cardiotoxicity.Stem cell therapy and breast cancer treatment: review of stem cell research and potential therapeutic impact against cardiotoxicities due to breast cancer treatment.

P2860

Q24234511-022D9204-897A-4DA4-A309-080FF1301D93 Q26743433-A9561796-EAFB-4455-92B4-F85A1889AA09 Q26750878-6D4E6E79-4793-4488-817B-031E9DBA81B7 Q26768272-618E834E-7C2A-4948-94C6-DBD4652439F2 Q26778343-3B9BD7BD-7B6D-4BA8-8C51-900243546D0A Q26851957-C57A3691-6C4B-4ECA-8B10-11B62A6571F6 Q26865766-3A630C1A-FC92-478D-88AB-84AC693F0C4E Q26998273-91838E8E-AF95-4D2C-8008-21995128CC09 Q27010466-15FAAE18-3477-4DD7-855B-3F5935D27C75 Q27013665-2CEEF882-E2E7-4478-86B1-B363C38005BA Q28068290-59C7C0DE-9FF8-4440-8B36-B212FF203A3A Q28081385-45604455-8304-4299-856B-E7AFC71AAC5A Q28087776-BE86DBF2-FF1F-47EF-980B-41CACCD83D4C Q28543466-ACE6CCCC-4EA6-49EE-8233-88DF0FCE8A47 Q30248340-BA9A4F2C-2E06-4CC6-AA74-850EC361429C Q30276456-DC0B3154-9E04-4FEA-AFEF-D31C1C2D1011 Q30385954-F7A9ACD0-C756-429A-A8EF-409FBDCF925B Q30401812-34FAC095-2A85-4086-983C-C16304E24E2D Q30412756-7FE524AC-6599-4577-BE62-F4108A410782 Q30415201-F955A946-617A-4A34-A0F4-23942B3CD590 Q30426853-7E09A0F1-1858-4BC1-8368-B28E639C851A Q30427656-5723CFA9-F814-4541-9C94-8B5800F2464A Q30439608-5E111E74-E83C-4A4D-8B8A-9DC51AE8ABCC Q30446509-12F8279F-FAAD-4939-930F-E6DEF692DFF6 Q31120288-D53ABD39-450D-46E0-B230-52F0218B3945 Q33565936-CE1E6077-B660-49B2-A89C-6966D82D1321 Q33574136-C3B9B47B-ABB8-4DA1-A260-03C750CA8548 Q33658456-F9BDDA31-0FEF-44AC-9A5A-A2F0B3DC8195 Q33701308-5DDA05A2-C4C1-4D0E-A00E-56CD36322A5A Q33752979-BAB0EB45-AF46-4518-8298-A83A51667A90 Q33807542-C1A975EA-134D-4F7B-9E31-C61EC551ACC4 Q33815037-7E616353-62AB-439F-9CC9-EF1C97C71724 Q33896047-3D9709AD-7E46-4192-B6B8-BECD61B03F70 Q33922644-017B2EF9-53AE-4EE8-8BD9-C181E987E883 Q33930241-FCD45BF2-BAAF-4059-8E43-070D35B5E128 Q34001004-6808C01B-5521-49A5-9403-A749B975BC24 Q34046881-B71ECE3B-620E-43D5-9252-C90450F3BED8 Q34102834-FB859BAF-EE15-460F-85FF-8919A8094191 Q34258080-5637700E-05EB-4991-B1C2-C81EC8AA97A3 Q34441749-A1E5D0CA-EC52-4052-A597-69D500B39DEA

P2860

Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.

http://www.wikidata.org/entity/Q33527690

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Anthracycline-induced cardiomy ...... onse to pharmacologic therapy.

@ast

Anthracycline-induced cardiomy ...... onse to pharmacologic therapy.

@en

Anthracycline-induced cardiomy ...... onse to pharmacologic therapy.

@nl

type

label

Anthracycline-induced cardiomy ...... onse to pharmacologic therapy.

@ast

Anthracycline-induced cardiomy ...... onse to pharmacologic therapy.

@en

Anthracycline-induced cardiomy ...... onse to pharmacologic therapy.

@nl

prefLabel

Anthracycline-induced cardiomy ...... onse to pharmacologic therapy.

@ast

Anthracycline-induced cardiomy ...... onse to pharmacologic therapy.

@en

Anthracycline-induced cardiomy ...... onse to pharmacologic therapy.

@nl

P1433

Q33527690-645208EA-0F2A-443D-A5DD-59D31CC49F30

P1476

Q33527690-4E56DB8D-11CB-4BD3-BC3A-44224B5010FC

P2093

Q33527690-28AE39BE-DC49-4268-AFEE-27E19AECB69D

Q33527690-2E0A2F98-749E-458E-95D1-A64744064FE6

Q33527690-354F60DB-1F8C-408A-80B0-800C87A0D4B4

Q33527690-42D5CA18-697A-4C58-A428-33CB12969B7C

Q33527690-61C96F52-741D-4240-9890-9C70D2B2DAD9

Q33527690-79D7791D-55E9-4CE6-97A6-1F73FF77DE80

Q33527690-B5C18718-658C-47A4-A238-453B662986E6

Q33527690-C4FC97B3-AFFF-4E8C-8C3D-EC5903E3965D

Q33527690-C9EF7396-794A-4341-A7C1-B9A25E6FD348

P304

Q33527690-EDD30BBD-9510-40D4-868A-347C55D9FFF5

P31

Q33527690-96C4EF9E-8385-4773-932A-5A5A3ACE6465

P356

Q33527690-ED532B05-9D74-463C-8EB8-CF9AF1F44EE4

P407

Q33527690-7932C1F2-3819-4DD9-AC7A-912BCA8EC935

P433

Q33527690-0A3CFBED-B08C-4B4A-A02B-B7E9816BFD5C

P478

Q33527690-7EEC7E16-E576-4B95-9560-2FAA3597858D

P50

Q33527690-CC9ACFB6-CA56-496C-8A7E-B0DFD8E06E9B

P577

Q33527690-BCCC2F6A-DEC5-49FF-A258-3AF46D575A4F

P5875

Q33527690-66FDCAD9-1972-4210-8A22-D98B2C88875F

P698

Q33527690-BDB92E12-FE9C-4E89-A1A6-EA5782165F35

P921

Q33527690-1683854C-64C6-4D22-8372-88623BDDA1C7

P356

J.JACC.2009.03.095

P1433

Journal of the American College of Cardiology

P1476

Anthracycline-induced cardiomy ...... onse to pharmacologic therapy.

@en

P2093

Alessandro Colombo

http://www.w3.org/2001/XMLSchema#string

Carlo M Cipolla

http://www.w3.org/2001/XMLSchema#string

Cesare Fiorentini

http://www.w3.org/2001/XMLSchema#string

Daniela Cardinale

http://www.w3.org/2001/XMLSchema#string

Fabrizio Veglia

http://www.w3.org/2001/XMLSchema#string

Gaia De Giacomi

http://www.w3.org/2001/XMLSchema#string

Giuseppina Lamantia

http://www.w3.org/2001/XMLSchema#string

Maurizio Civelli

http://www.w3.org/2001/XMLSchema#string

Nicola Colombo

http://www.w3.org/2001/XMLSchema#string

P304

213-220

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JACC.2009.03.095

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41190490

http://www.w3.org/2001/XMLSchema#string

P698

20117401

http://www.w3.org/2001/XMLSchema#string

P921